ID   NCI-H508 R2 Cetux
AC   CVCL_A2CG
SY   NCIH508 R2 Cetux
DR   cancercelllines; CVCL_A2CG
DR   Cosmic; 2841374
DR   Wikidata; Q105510319
RX   PubMed=25623215;
CC   Population: Caucasian.
CC   Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly596Arg (c.1786G>C); ClinVar=VCV000375943; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Abdominal wall; UBERON=UBERON_0003697.
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1564 ! NCI-H508
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821;
RA   Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I.,
RA   Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M.,
RA   Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J.,
RA   Dalmases A., Bellmunt J., De Fabritiis G., Rovira A.,
RA   Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.;
RT   "Emergence of multiple EGFR extracellular mutations during cetuximab
RT   treatment in colorectal cancer.";
RL   Clin. Cancer Res. 21:2157-2166(2015).
//